Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system. Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, the Flivas™ agent for dysuria, the Bredinin™ immunosuppressant, the Toledomin™ antidepressant, and the Eril™ Rho-kinase inhibitor, each of which has a competitive position in its respective market.
The product information contained in this website is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin. Product availability, names, indications, and presentations may vary from country to country.
TERIBONE™ (teriparatide acetate)
Teribone™ is a human parathyroid hormone preparation that facilitates bone formation, for the indication of osteoporosis with high risk of fracture. With weekly or twice weekly subcutaneous injections, Teribone™ decreases the risk of developing new vertebral fracture.
RECLAST® (zoledronic acid)
Reclast® is a bisphosphonate agent that suppresses bone resorption, for the treatment of osteoporosis. Reclast® is capable of a year-long treatment with once-a-year intravenous infusion.
Reclast® is a registered trademark of Novartis.
ELCITONIN™ (elcatonin) Injection 20S
Elcitonin™ Injection 20S has superior efficacy in alleviating pain associated with osteoporosis while suppressing its concomitant bone loss.
RECOMODULIN™ (thrombomodulin alfa)
Recomodulin™ is the world’s first thrombomodulin agent produced through genetic engineering. Recomodulin™ improves the symptoms of disseminated intravascular coagulation (DIC) by regulating coagulation through activation of protein C.
Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.
Kevzara® is a registered trademark of Sanofi Biotechnology.
Flivas™ is indicated for the treatment of dysuria accompanying benign prostatic hyperplasia. Flivas™ improves the symptoms of difficulty in urination, nocturia, and incomplete emptying by decreasing urethral pressure.
Bredinin™ improves abnormalities in immune function. In addition to suppression of immune response following renal transplantation, Bredinin™ ameliorates renal symptoms such as proteinuria in nephrotic syndrome and lupus nephritis and reduces joint swelling, pain, and stiffness in rheumatoid arthritis.
TOLEDOMIN™ (milnacipran hydrochloride)
Toledomin™ is a novel antidepressant and the first serotonin-norepinephrine reuptake inhibitor (SNRI) to be approved in Japan.
Toledomin™ is a registered trademark of Pierre Fabre Medicament SA.
ERIL™ (fasudil hydrochloride hydrate)
Eril™, a Rho-kinase inhibitor, improves cerebral vasospasm and delayed cerebral ischemic symptoms after subarachnoid hemorrhage by inhibiting the activation of neutrophils and suppressing the contraction of vascular smooth muscle.
Famvir® is an anti-herpes virus agent that improves the rash and pain that occurs in the acute phase of herpes zoster. As of February 2013, Famvir® is also indicated in Japan for the treatment of herpes simplex.
Famvir® is marketed in Japan by Maruho Co., Ltd., a leader in the field of dermatology.
Famvir® is a registered trademark of Novartis.